Literature DB >> 11266932

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

W Jacobsen1, N Serkova, B Hausen, R E Morris, L Z Benet, U Christians.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11266932     DOI： 10.1016/s0041-1345(00)02116-3

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  26 in total

1.  A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Authors:  Stacy Moulder; Gregory Gladish; Joe Ensor; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli; James L Murray; Daniel Booser; Sharon H Giordano; Abeena Brewster; Julia Moore; Edgardo Rivera; Gabriel N Hortobagyi; Hai T Tran
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.

Authors:  Ravindran Kanesvaran; Kevin Watt; James D Turnbull; Andrew J Armstrong; Michael Cohen Wolkowiez; Daniel J George
Journal:  Clin Genitourin Cancer       Date:  2014-12-30       Impact factor: 2.872

3.  Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.

Authors:  Dirk Jan A R Moes; Rogier R Press; Jan den Hartigh; Tahar van der Straaten; Johan W de Fijter; Henk-Jan Guchelaar
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

4.  Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.

Authors:  Tomoyuki Mizuno; Tsuyoshi Fukuda; Uwe Christians; John P Perentesis; Maryam Fouladi; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-12-20       Impact factor: 4.335

5.  Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Authors:  Michael A Gordon; Nicholas C D'Amato; Haihua Gu; Beatrice Babbs; Julia Wulfkuhle; Emanuel F Petricoin; Isela Gallagher; Ting Dong; Kathleen Torkko; Bolin Liu; Anthony Elias; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

6.  More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Authors:  Ida Robertsen; Anders Asberg; Tone Granseth; Nils Tore Vethe; Fatemeh Akhlaghi; Mwlod Ghareeb; Espen Molden; Morten Reier-Nilsen; Hallvard Holdaas; Karsten Midtvedt
Journal:  Transplantation       Date:  2014-06-27       Impact factor: 4.939

Review 7.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 8.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

9.  The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.

Authors:  Chie Emoto; Tsuyoshi Fukuda; Raja Venkatasubramanian; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

10.  Everolimus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.